New clinical and biological developments in lung cancer
Aims : This session is built from abstracts published on the ERS Congress platform from 23 August, in a PowerPoint format with a pre-recorded audio narration. The live session is scheduled from September 5-7 and each presenter will have a 5-minutes live, slide show presentation followed at the end of the session by 30-minutes general discussion.
This session includes the Best Abstract for Assembly 11.01 - Lung cancer, entitled "Spirometry and under-diagnosis of COPD in a lung cancer screening cohort”
Pulmonary function testing, Cell and molecular biology, Epidemiology, Endoscopy and interventional pulmonology, Imaging, General respiratory patient care
Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study.
R. Gijtenbeek(Leeuwarden, Netherlands)